{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T07:44:41Z","timestamp":1794987881854,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Effective systemic therapies suppress toxic light chain production leading to an increased proportion of patients with light chain (AL) amyloidosis who survive longer albeit with end-stage renal disease. There is a critical need to identify patients in this population who benefit from renal transplantation. This multicenter, observational study from five countries includes 237 patients with AL amyloidosis who underwent renal transplantation between 1987 and 2020. With a median follow-up of 8.5 years, the median overall survival from renal transplantation was 8.6 years and was significantly longer in patients with complete and very good partial hematologic responses (CR\u2009+\u2009VGPR) compared to less than VGPR (9 versus 6.8 years; HR: 1.5,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.04 [95% CI: 1\u20132.1]) at renal transplantation. Median graft survival was 7.8 years and was better in the CR\u2009+\u2009VGPR group (8.3 vs 5.7 years, HR: 1.4,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.05 [95% CI: 1\u20132]). The frequency and time to amyloid recurrence in the graft was also lower (16% vs 37%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01) and longer (median time not achieved vs 10 years,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001) in the CR\u2009+\u2009VGPR group. Comparing CR vs. VGPR there was no difference in overall or graft survival. Although 69 patients (29%) experienced hematologic relapse, treatment effectively prevented graft loss in the majority (87%). Renal transplantation in selected AL amyloidosis patients is associated with extended overall and renal graft survival. Patients with hematologic CR or VGPR have the most favorable outcomes, and these patients should be considered for renal transplantation.\n                  <\/jats:p>","DOI":"10.1038\/s41408-022-00714-5","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T05:43:32Z","timestamp":1660887812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8758-0823","authenticated-orcid":false,"given":"Andrea","family":"Havasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7903-1106","authenticated-orcid":false,"given":"Cihan","family":"Heybeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avital","family":"Angel-Korman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-2445","authenticated-orcid":false,"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-7237","authenticated-orcid":false,"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bridoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insara","family":"Jaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gutgarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2036-1749","authenticated-orcid":false,"given":"Hani","family":"Hassoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Levinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2268-9422","authenticated-orcid":false,"given":"Paolo","family":"Milani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-5138","authenticated-orcid":false,"given":"Giovanni","family":"Palladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7680-3254","authenticated-orcid":false,"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-6746","authenticated-orcid":false,"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4853-5579","authenticated-orcid":false,"given":"Stefan","family":"Sch\u00f6nland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaya","family":"Veelken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Pogrebinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheorghe","family":"Doros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":false,"given":"Heather","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"714_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583\u201396.","journal-title":"N Engl J Med"},{"key":"714_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, Sch\u00f6nland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Prim. 2018;4:38.","journal-title":"Nat Rev Dis Prim"},{"key":"714_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15424-3","volume":"7","author":"E Imperlini","year":"2017","unstructured":"Imperlini E, Gnecchi M, Rognoni P, Sabido E, Ciuffreda MC, Palladini G, et al. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Sci Rep. 2017;7:15661.","journal-title":"Sci Rep."},{"key":"714_CR4","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","volume":"29","author":"G Merlini","year":"2011","unstructured":"Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29:1924\u201333.","journal-title":"J Clin Oncol"},{"key":"714_CR5","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1093\/ndt\/gfp201","volume":"24","author":"MA Gertz","year":"2009","unstructured":"Gertz MA, Leung N, Lacy MQ, Dispenzieri A, Zeldenrust SR, Hayman SR, et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transpl. 2009;24:3132\u20137.","journal-title":"Nephrol Dial Transpl"},{"key":"714_CR6","doi-asserted-by":"publisher","first-page":"E458","DOI":"10.1002\/ajh.24464","volume":"91","author":"A Havasi","year":"2016","unstructured":"Havasi A, Stern L, Lo S, Sun F, Sanchorawala V. Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation. Am J Hematol. 2016;91:E458\u201360.","journal-title":"Am J Hematol"},{"key":"714_CR7","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","volume":"124","author":"G Palladini","year":"2014","unstructured":"Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124:2325\u201332.","journal-title":"Blood"},{"key":"714_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.2010.30.5235","volume":"29","author":"JH Pinney","year":"2011","unstructured":"Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, et al. Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol. 2011;29:674\u201381.","journal-title":"J Clin Oncol"},{"key":"714_CR9","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","volume":"336","author":"RA Kyle","year":"1997","unstructured":"Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N. Engl J Med. 1997;336:1202\u20137.","journal-title":"N. Engl J Med"},{"key":"714_CR10","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","volume":"100","author":"M Skinner","year":"1996","unstructured":"Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996;100:290\u20138.","journal-title":"Am J Med"},{"key":"714_CR11","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","volume":"118","author":"MT Cibeira","year":"2011","unstructured":"Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118:4346\u201352.","journal-title":"Blood"},{"key":"714_CR12","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","volume":"130","author":"GP Kaufman","year":"2017","unstructured":"Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130:900\u20132.","journal-title":"Blood"},{"key":"714_CR13","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/s41375-020-1006-7","volume":"35","author":"R Szalat","year":"2021","unstructured":"Szalat R, Sarosiek S, Havasi A, Brauneis D, Sloan JM, Sanchorawala V. Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis. Leukemia. 2021;35:916\u20139.","journal-title":"Leukemia"},{"key":"714_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ajh.23898","volume":"90","author":"GP Kaufman","year":"2015","unstructured":"Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol. 2015;90:181\u20136.","journal-title":"Am J Hematol"},{"key":"714_CR15","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/00007890-198612000-00005","volume":"42","author":"A Pasternack","year":"1986","unstructured":"Pasternack A, Ahonen J, Kuhlback B. Renal transplantation in 45 patients with amyloidosis. Transplantation. 1986;42:598\u2013601.","journal-title":"Transplantation"},{"key":"714_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0046-8177(81)80175-X","volume":"12","author":"SA Dorman","year":"1981","unstructured":"Dorman SA, Gamelli RL, Benziger JR, Trainer TD, Foster RS. Systemic amyloidosis involving two renal transplants. Hum Pathol. 1981;12:735\u20138.","journal-title":"Hum Pathol"},{"key":"714_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.kint.2018.09.021","volume":"95","author":"A Angel-Korman","year":"2019","unstructured":"Angel-Korman A, Stern L, Sarosiek S, Sloan JM, Doros G, Sanchorawala V, et al. Long-term outcome of kidney transplantation in AL amyloidosis. Kidney Int. 2019;95:405\u201311.","journal-title":"Kidney Int"},{"key":"714_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0325-2","volume":"10","author":"OC Cohen","year":"2020","unstructured":"Cohen OC, Law S, Lachmann HJ, Sharpley F, Ravichandran S, Mahmood S, et al. The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis. Blood Cancer J. 2020;10:60.","journal-title":"Blood Cancer J"},{"key":"714_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.kint.2020.06.036","volume":"99","author":"C Heybeli","year":"2021","unstructured":"Heybeli C, Bentall A, Wen J, Alexander MP, Buadi FK, Cosio FG, et al. A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. Kidney Int. 2021;99:707\u201315.","journal-title":"Kidney Int"},{"key":"714_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/ndt\/gfaa293","volume":"36","author":"S Law","year":"2021","unstructured":"Law S, Cohen O, Lachmann HJ, Rezk T, Gilbertson JA, Rowczenio D, et al. Renal transplant outcomes in amyloidosis. Nephrol Dial Transpl. 2021;36:355\u201365.","journal-title":"Nephrol Dial Transpl"},{"key":"714_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/bjh.16246","volume":"188","author":"IJ Sathick","year":"2020","unstructured":"Sathick IJ, Rosenbaum CA, Gutgarts V, Landau H. Kidney transplantation in AL Amyloidosis: is it time to maximize access? Br J Haematol. 2020;188:e1\u20134.","journal-title":"Br J Haematol"},{"key":"714_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79:319\u201328.","journal-title":"Am J Hematol"},{"key":"714_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1373\/clinchem.2008.117143","volume":"55","author":"G Palladini","year":"2009","unstructured":"Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009;55:499\u2013504.","journal-title":"Clin Chem"},{"key":"714_CR24","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541\u20139.","journal-title":"J Clin Oncol"},{"key":"714_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","volume":"28","author":"G Palladini","year":"2021","unstructured":"Palladini G, Schonland SO, Sanchorawala V, Kumar S, Wechalekar A, Hegenbart U, et al. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid. 2021;28:1\u20132.","journal-title":"Amyloid"},{"key":"714_CR26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461\u201370.","journal-title":"Ann Intern Med"},{"key":"714_CR27","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1200\/JCO.2007.12.9866","volume":"26","author":"JJ Dignam","year":"2008","unstructured":"Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol. 2008;26:4027\u201334.","journal-title":"J Clin Oncol"},{"key":"714_CR28","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","volume":"9","author":"Kidney Disease: Improving Global Outcomes Transplant Work G.","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes Transplant Work G. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transpl. 2009;9:S1\u2013155.","journal-title":"Am J Transpl"},{"key":"714_CR29","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/ndt\/gfr067","volume":"26","author":"SM Herrmann","year":"2011","unstructured":"Herrmann SM, Gertz MA, Stegall MD, Dispenzieri A, Cosio FC, Kumar S, et al. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transpl. 2011;26:2032\u20136.","journal-title":"Nephrol Dial Transpl"},{"key":"714_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00385-0","volume":"10","author":"A Staron","year":"2020","unstructured":"Staron A, Connors LH, Zheng L, Doros G, Sanchorawala V. Race\/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer J. 2020;10:118.","journal-title":"Blood Cancer J"},{"key":"714_CR31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1053\/j.ackd.2016.07.001","volume":"23","author":"JH Wang","year":"2016","unstructured":"Wang JH, Skeans MA, Israni AK. Current status of kidney transplant outcomes: dying to survive. Adv Chronic Kidney Dis. 2016;23:281\u20136.","journal-title":"Adv Chronic Kidney Dis"},{"key":"714_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/ajt.14557","volume":"18","author":"A Hart","year":"2018","unstructured":"Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Robinson A, et al. OPTN\/SRTR 2016 Annual Data Report: Kidney. Am J Transpl. 2018;18:18\u2013113.","journal-title":"Am J Transpl"},{"key":"714_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/TP.0000000000001930","volume":"102","author":"D Sawinski","year":"2018","unstructured":"Sawinski D, Lim MA, Cohen JC, Locke JE, Weiss B, Hogan JJ, et al. Patient and kidney allograft survival in recipients with end stage renal disease from Amyloidosis. Transplantation. 2018;102:300\u20139.","journal-title":"Transplantation"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00714-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00714-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00714-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T15:11:10Z","timestamp":1669216270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00714-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["714"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00714-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"VS: Research support from Celgene, Takeda, Caelum, Prothena, Janssen. Advisory boards of Regeneron, Abbvie, Janssen, Caelum; Consultancy for Pfizer. UH: Grants from Janssen, Prothena, and Pfizer. Advisory boards for Pfizer, Janssen, and Prothena. Honoraria from Janssen, Pfizer, Alnylam, and Akcea, Research funding from Janssen. SOS: Travel grants from Janssen, MSD, Prothena and Takeda, Advisory boards for Janssen and Prothena. Honoraria from Janssen, Prothena, Pfizer, and Takeda. Research funding from Sanofi and Janssen. HL: Advisory board for Janssen, Celgene, Sanofi, Takeda, Caelum, Pfizer. Honoraria from Pfizer and Sanofi. Research funding from Takeda. GP: Honoraria and advisory board of Janssen-Cilag, Honoraria Pfizer and Siemens. PM: Speaker honoraria Janssen-Cilag. Travel support from Celgene. FB: Honoraria from Astra-Zeneca and Janssen. AH: At the time of publication employed by Alnylam Pharmaceuticals. At the time of data collection, analysis and writing of the paper no disclosure.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}